Current industry best practices and FDA guidelines urge therapeutic antibody developers to use affinity-purified polyclonal antibodies in anti-drug assays for immunogenicity studies as well as controls for ongoing drug monitoring.
MBS delivers sensitive and specific positive ADA controls through:
- Dedicated project management of polyclonal antibody development
- Goal-driven immunization strategies
- Advanced, application-specific screening of serum samples
- Custom affinity purification
- Lifetime supply of antibody generated within 5 months
Learn More about Polyclonal Antibody Development
Read the MBS Biology of Antibodies Blog on the Detection of Therapeutic Antibodies
The post Anti-Drug Antibody Reagent Development appeared first on Maine Biotechnology.
